Carbamazepine is a tricyclic anticonvulsant and has been widely used for the treatment of psychiatric disorders in addition to epilepsy, trigeminal neuralgia, dystonia, and urolithiasis. Due to the widespread use of carbamazepine, its toxic side effects have received increasing attention. Commonly reported are nausea and vomiting, appetite changes, abdominal distension and constipation caused by carbamazepine, which are mostly mild and transient reactions and generally do not require discontinuation of the drug. The most common skin lesions are eczema, dermatomyositis, exfoliative dermatitis, etc., which are cured after discontinuation of the drug, use of hormones and symptomatic treatment. In addition, carbamazepine has been reported to cause leukopenia, granulocyte deficiency, eosinophilia, thrombocytopenia, and aplastic anemia, which are mostly recovered after discontinuation of the drug. Rarely, carbamazepine has been reported to directly inhibit erythrocyte uroporphyrinogen-I synthase, causing disorders of porphyrin metabolism and producing a class of acute interstitial porphyrias, which can be improved after discontinuation of the drug. In addition, carbamazepine has been reported to cause systemic lupus erythematosus, and carbamazepine has been reported to cause neutrophilia or leukemia-like reactions. Cardiac rhythm disturbances, conduction block, and heart failure have also been reported with carbamazepine treatment, often due to the damaging effects of drug overdose on the heart. Nystagmus, slurred speech, dyskinesia, vertigo, drowsiness, and confusion due to carbamazepine have been reported repeatedly. Occasionally, carbamazepine has been reported to cause hematuria, proteinuria, glycosuria and elevated non-protein nitrogen and decreased water excretion, and hyponatremia. Erythromycin can increase the blood concentration of carbamazepine, and even toxic reactions can occur. In addition, there are reports of neurotoxic reactions to carbamazepine induced by isoptin.